Fresenius Medical Care First Quarter 2024 Earnings: EPS Beats Expectations

Fresenius Medical Care First Quarter 2024 Earnings: EPS Beats Expectations

Fresenius Medical Care (ETR:FME) First Quarter 2024 Results

Key Financial Results

  • Revenue: €4.73b (flat on 1Q 2023).

  • Net income: €71.0m (down 18% from 1Q 2023).

  • Profit margin: 1.5% (down from 1.8% in 1Q 2023).

  • EPS: €0.24 (down from €0.29 in 1Q 2023).

Fresenius Medical Care First Quarter 2024 Earnings: EPS Beats ExpectationsFresenius Medical Care First Quarter 2024 Earnings: EPS Beats Expectations

earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fresenius Medical Care EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Germany.

Performance of the German Healthcare industry.

The company’s shares are down 5.5% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company’s balance sheet. See our latest analysis on Fresenius Medical Care’s balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Leave a Reply